UK ’s NICE recommends Janssen’s Imbruvica as treatment for adults with CLL

UK ’s National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending Janssen’s Imbruvica (ibrutinib), as a treatment option for adults with chronic lymphocytic leukaemia (CLL).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news